DIRS.INFO The most relevant business & tech news

☆ Here are Tuesday's biggest analyst calls: Apple, Nvidia, Amazon, Tesla, Seagate, Boston Beer, Planet Fitness & more
▼ + stars: | 2024-05-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Wells Fargo reiterates Nvidia as overweight Wells increased its price target on Nvidia to $1,150 per share from $970. Jefferies upgrades Boston Beer to buy from hold Jefferies said in its upgrade of the beverage company that it sees "multiple expansion." Bank of America reiterates Apple as buy Bank of America said it's sticking with its buy rating on shares of Apple. JPMorgan upgrades Planet Fitness to overweight from neutral JPMorgan said in its has increased confidence in Planet Fitness' growth. JPMorgan upgrades Vtex to overweight from neutral JPMorgan said it sees an attractive entry point for the software-as-a-service company.

Persons: Tesla, Goldman Sachs, Goldman, it's, Wells, ests, Jefferies, Beer, Roth, Morgan Stanley, GXO's, Baird, Oppenheimer, Edwards Organizations: Barclays, Oncology, Fulcrum Therapeutics, ISI, Nvidia, Jefferies, Boston Beer, GXO Logistics, Bank of America, Apple, HSBC, Citi, Weatherford, Energy, JPMorgan, LT, Fortrea Holdings, Edison International, RBC, North, Deutsche Bank, Amazon, Deutsche, Western Digital, Seagate Locations: China, North America

☆ Morgan Stanley says M&A will rebound and these stocks have an 'elevated likelihood' of a takeover
▼ + stars: | 2024-03-05 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Global mergers and acquisition activity will soar this year, and several names could benefit from the comeback, according to Morgan Stanley. The firm expects global M & A volume activity to rise by 50% this year compared to 2023. "We believe that a cyclical and structural rebound in M & A is coming," Morgan Stanley said in a note titled "Stocks with Elevated Likelihood of Receiving an Offer," which was released Monday. Morgan Stanley pointed out that 2021 to 2023 could have seen a drop of activity worth between $4 trillion and $11 trillion. Morgan Stanley said it has no information about M & A activity involving the companies.

Persons: Morgan Stanley, Morgan, Stephen Ju, Morgan Stanley's Organizations: Health, Sarepta Therapeutics, Tenet Healthcare, Analysts, BMO Capital Markets, UBS, Hertz Global Holdings Locations: Europe

☆ Comeback stocks: These names have jumped to start 2024 after falling last year
▼ + stars: | 2024-02-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

The Russell 1000 , which tracks the top 1,000 largest companies — large- and mid-cap names — is up about 3% in 2024. With this in mind, CNBC Pro screened for the stocks making a comeback in 2024. However, the consensus price target is just 4.6% from its current levels — putting into question whether there's more room for upside. Just 35.7% of analysts are bullish on the shares, and the average price target implies shares can grow just 4.3%. Sarepta Therapeutics has soared 27.4% this year — and it could jump 20.1% more according to its consensus price target, per LSEG.

Persons: Russell, they're, Merck's, Sarepta Organizations: CNBC Pro, Pharmaceutical, Merck, Verizon, Barclays, VZ, LSEG, Novo Nordisk, Sarepta Therapeutics Locations: Novo

☆ Cramer's Lightning Round: 'Too much hype' for C3.ai
▼ + stars: | 2023-11-14 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon HubSpot's year-to-date stock performance. Stock Chart Icon Stock chart icon Albemarle's year-to-date stock performance. Stock Chart Icon Stock chart icon Chewy's year-to-date stock performance. Stock Chart Icon Stock chart icon Leonardo DRS's year-to-date stock performance. Stock Chart Icon Stock chart icon CrowdStrike's year-to-date stock performance.

Persons: it's, Leonardo DRS's, Leonardo DRS, Brown, Forman, I've, They're, I'm, they're, Tom Siebel, George Kurtz Organizations: New York Community, New York Community Bancorp, Therapeutics, Sarepta Therapeutics, US Bancorp

☆ Insider Buys: Lumen, Air Products, Inari, Remitly and Sarepta
▼ + stars: | 2023-11-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailInsider Buys: Lumen, Air Products, Inari, Remitly and SareptaHosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m. ET on CNBC.

Persons: Brian Sullivan, “ Organizations: Products, CNBC

Executives of some beaten-down companies, including one battered biotech name and a popular soft drinks maker, scooped up shares of their own stock in the past week. Here are the top insider buys: Energy Transfer — Executive Chairman Kelcy Warren bought one million shares Monday at $13.53 per share for a total value of $13.53 million. Shares are up more than 2% over the past month. Enstar Group CEO bought swathes of shares Wednesday, the day after the company reported its earnings for the third quarter. The stock has gained about 8% so far this year and shares are up roughly 4% over the past month.

Persons: Kelcy Warren, Dominic F, Silvester, Nigel W, Morris, Richard Barry, Verity, Douglas Ingram, Keurig Dr Pepper, Timothy P, Cofer, Dr Pepper's, Dr Pepper —, Dr Pepper, Mott's —, Enstar Organizations: CNBC Pro, —, Global, Therapeutics, Remitly, FDA, U.S . Securities, Exchange, Enstar Locations: Canada

☆ Beware these companies due to report earnings that have negative profit momentum
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

CNBC Pro screened for the S & P 500 companies still reporting next week that analysts have expressed the most caution on — by cutting their earnings estimates ahead of the reports. Analyst consensus earnings estimates are down at least 5% over the past three months. Analyst consensus earnings estimates are down at least 5% over the past six months. CTLT YTD mountain Catalent YTD chart "Catalent (CTLT) became a very noticeable laggard in the life science space about fifteen months ago. Meat producer Tyson Foods , which is due to report earnings premarket on November 13, was also among the stocks with negative earnings momentum.

Persons: Gordon Haskett, Don Bilson, Bilson, Catalent, Michael Lasser, Lasser, Morgan Stanley, BBWI, Alex Straton, Tyson Foods, — CNBC's Michael Bloom Organizations: CNBC Pro, Biotechnology, Sarepta Therapeutics, Dystrophy, UBS, 3Q, Body Locations: Columbus , Ohio, Bath

☆ Stocks making the biggest moves after hours: SolarEdge, Qualcomm, Etsy, Clorox and more
▼ + stars: | 2023-11-01 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

SolarEdge — The solar stock cratered 23% after SolarEdge posted a dismal third-quarter report and outlook for the current quarter's revenue. SolarEdge lost 55 cents per share, excluding items, while analysts polled by LSEG, formerly known as Refinitiv, forecast a gain of 89 cents per share. The company guided revenue for the current quarter to between $300 million and $350 million, well under the $688 million anticipated by analysts. Qualcomm surpassed analysts' estimates in its fiscal fourth quarter, reporting adjusted earnings of $2.02 per share on revenue of $8.67 billion. Etsy beat analysts' estimates for earnings in the third quarter but fell short of Wall Street's expectations on revenue.

Persons: SolarEdge, LSEG, Josh Silverman, Etsy, Roku, Roku's, DoorDash, Clorox, Sarepta, FactSet, Darla Mercado, Sarah Min, Jesse Pound, Scott Schnipper Organizations: LSEG, Revenue, Qualcomm —, Qualcomm, Electronic Arts, Arts, Wall Street, Tandem Diabetes Care, Ritz, Therapeutics Locations: FactSet

☆ Former FDA commissioner Dr. Scott Gottlieb on the future of gene therapy
▼ + stars: | 2023-11-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFormer FDA commissioner Dr. Scott Gottlieb on the future of gene therapyFormer FDA commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of gene therapy, after Sarepta Therapeutics revealed new data for its Duchenne Muscular Dystrophy gene therapy fell short of expectations, the state of Covid-19, and more.

Persons: Scott Gottlieb Organizations: Former, Sarepta Therapeutics Locations: Covid

Six of the 11 major S&P 500 sectors were trading lower, with information technology (.SPLRCT) leading losses. Pfizer's shares (PFE.N) fell 1.5% after the drugmaker reported its first quarterly loss since 2019. U.S. equities are tracking their third straight month in the red, with the S&P 500 (.SPX) and the Nasdaq (.IXIC) on course for their worst October since 2018. The Fed kicks off a two-day monetary policy meeting on Tuesday. The Fed's commentary on Wednesday would be crucial in assessing how long monetary policy could stay restrictive amid recent signs of economic strength.

Persons: Brendan McDermid, Andrew Hunter, Amruta Khandekar, Shashwat Chauhan, Saumyadeb Chakrabarty, Shounak Dasgupta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Corp, Dow, Nasdaq, Federal, Nvidia, Microsoft, Caterpillar, Chicago PMI, Capital Economics, Dow Jones, PDD Holdings, VF Corp, Vans, Arista Networks, Sarepta Therapeutics, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

☆ Murky road ahead for Duchenne gene therapy as confirmatory trial misses main goal
▼ + stars: | 2023-10-31 | by ( Meg Tirrell | ) edition.cnn.com time to read: +4 min

Sarepta gave the one-time drug a price tag of $3.2 million, making it the second most-expensive medicine in the world. DMD affects one in 3,500 to 5,000 newborns, mostly boys because of the way it’s inherited, according to Johns Hopkins Medicine. The primary goal of the confirmatory trial was improvement on a measure known as the North Star Ambulatory Assessment, a scale of how well kids can stand, walk and perform other movements. The difference wasn’t statistically significant, meaning technically the study failed to meet its main goal. The company said no new safety issues emerged in the trial, which it called EMBARK.

Persons: Doug Ingram, ” Ingram, Sarepta, “, Dr, Sanjay Gupta, Ingram, ” Organizations: CNN, US Food and Drug Administration, Sarepta Therapeutics, FDA, Johns Hopkins Medicine, North Star, CNN Health

☆ Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals
▼ + stars: | 2023-06-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goalsDoug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get revoked, and more.

Persons: Doug Ingram, Ingram Organizations: Sarepta Therapeutics

☆ Analysts love these Nasdaq stocks as benchmark wraps up best first half since 1983
▼ + stars: | 2023-06-27 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

The tech-heavy index has soared nearly 29% this year and is currently on pace for its best first half since 1983. That year, the Nasdaq rallied 37.1% in the first half and finished 1983 up nearly 20%. Their average price target implies about 34% upside compared with current levels. Three-quarters of analysts covering the stock rate it a buy, and the average price target indicates 30% upside over the next 12 months. Of the 14 analysts covering the stock, 71% rate it a buy, while the average analyst price target implies upside of nearly 64%.

Persons: Ambrx, FANG, Canaccord Genuity Organizations: Nasdaq, Apple, Google, Nvidia, CNBC Pro, Diamondback Energy, Mobileye, Sarepta Therapeutics, U.S . Food, Drug Administration Locations: Texas, U.S

☆ Sarepta slumps as concerns emerge around upcoming gene therapy data
▼ + stars: | 2023-06-23 | by ( ) www.reuters.com time to read: +2 min

June 23 (Reuters) - Sarepta Therapeutics shares (SRPT.O) slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use. The U.S. health regulator had on Thursday granted Sarepta's Elevidys therapy accelerated approval to treat DMD patients aged between 4 and 5 years who can walk, contrary to the company's application for all patients who can walk. Sarepta's gene therapy is the first of its kind for DMD, an inherited progressive muscle-wasting disorder that almost always affects young boys. Elevidys, a one-time treatment, is expected to change the way that DMD patients are treated as current therapies require regular use. William Blair's Tim Lugo called the treatment "transformational for Duchenne's patients" and "a significant opportunity for Sarepta".

Persons: Sarepta's, Gavin Clark, Gartner, William Blair's Tim Lugo, Leroy Leo, Khushi, Devika Organizations: Sarepta Therapeutics, Food and Drug, BioMarin Pharmaceuticals, Thomson Locations: U.S, Bengaluru

☆ Catalent cuts annual forecast hurt by operational challenges
▼ + stars: | 2023-05-19 | by ( ) www.reuters.com time to read: +2 min

May 19 (Reuters) - Catalent Inc (CTLT.N) cut its full-year net revenue and profit forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to both its annual sales and core profit forecasts earlier this month. The contract drug manufacturer now sees its full-year revenue in the range of $4.25 billion to $4.35 billion compared with its prior forecast of $4.63 billion to $4.88 billion. Catalent said it now sees adjusted net income for the year in the range of $187 million to $228 million, compared with the previous forecast of $567 million to $648 million. Shares of Catalent reversed losses to be up 7.7% at $34.63 before the bell. Reporting by Bhanvi Satija, Sriparna Roy and Pratik Jain in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.

☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
▼ + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.

☆ Gene-Therapy Investors Have a Powerful Ally: Patients
▼ + stars: | 2023-05-16 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Sarepta’s stock jumped after an FDA panel voted in favor of a drug to treat Duchenne muscular dystrophy. Photo: Kristoffer Tripplaar/Sipa USA/Associated PressImagine for a moment that you are an expert at a Food and Drug Administration advisory panel meeting trying to decide whether to vote in favor of a drug for a rare disease that robs boys of their ability to walk, eventually killing many of them by the time they reach young adulthood. During the meeting, you hear testimonials from doctors and patients, including a video showing a boy riding his bike years after receiving the therapy for the disease, known as Duchenne muscular dystrophy. At the same meeting, you also hear from FDA staff who warn you that the studies conducted by Sarepta Therapeutics don’t provide clear evidence that the drug is beneficial. They also highlight some safety concerns.

☆ Sarepta surges after FDA panel backs Duchenne gene therapy
▼ + stars: | 2023-05-15 | by ( ) www.reuters.com time to read: +2 min

May 15 (Reuters) - Shares of Sarepta Therapeutics (SRPT.O) soared 29% premarket on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy for a muscle-wasting genetic disorder. Eight of the 14 advisers to the Food and Drug Administration late Friday voted that the company had enough data to support an accelerated approval for its gene therapy for Duchenne muscular dystrophy (DMD). The vote came after FDA staff had earlier last week voiced concerns that the data from the company's mid-stage trial lacked "unambiguous evidence" about benefits from the therapy. TD Cowen analyst Ritu Baral expects an approval for the therapy, especially considering the FDA leadership's interest in promoting biomarker-based accelerated approvals for gene therapies. The FDA, often follows the advice of its expert advisers but is not obligated to do so, is slated to make a decision on accelerated approval by May 29.

☆ FDA board votes to approve gene therapy for Duchenne muscular dystrophy
▼ + stars: | 2023-05-15 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA board votes to approve gene therapy for Duchenne muscular dystrophyDavid Nierengarten, Wedbush Securities managing director, joins 'Closing Bell Overtime' to discuss Sarepta shares after the FDA panel votes to approve gene therapy for Duchenne muscular dystrophy.

☆ FDA reviewers raise doubts over data on Sarepta's gene therapy
▼ + stars: | 2023-05-10 | by ( Leroy Leo | ) www.reuters.com time to read: +2 min

May 10 (Reuters) - The U.S. Food and Drug Administration's staff reviewers raised concerns over limited data on Sarepta Therapeutics Inc's (SRPT.O) gene therapy for a muscle-wasting disorder, ahead of a meeting of the agency's advisers on Friday. The agency's staff on Wednesday highlighted several issues with the data and said that existing studies did not provide "unambigious evidence" that the gene therapy will benefit patients with Duchenne muscular dystrophy. The FDA also highlighted that DMD, a rare disorder that mainly affects young boys, is an urgent unmet medical need. The advisory committee's vote on Friday and an eventual decision by the FDA is seen as a test of the agency's accelerated approval pathway for gene therapies. Sarepta has three drugs available for the disease for people with different types of genetic mutations but they have to be given as weekly intravenous infusion, while the experimental gene therapy is a one-time treatment.

☆ Sarepta shares tumble as concerns mount over FDA approval on gene therapy
▼ + stars: | 2023-04-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSarepta shares tumble as concerns mount over FDA approval on gene therapyCNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.

☆ Sarepta drops as report says FDA almost rejected under-review gene therapy
▼ + stars: | 2023-04-13 | by ( ) www.reuters.com time to read: +1 min

April 13 (Reuters) - Sarepta Therapeutics Inc's shares (SRPT.O) fell more than 6% on Thursday as Stat News reported that the U.S. health regulator's staff were inclined to reject the company's gene therapy which is currently under review. Some staff at the U.S. Food and Drug Administration (FDA) had reached a "non-binding conclusion" that Sarepta's gene therapy should not be given approval, prompting FDA official Peter Marks to intervene and instead schedule an advisory meeting on May 12, Stat News reported, citing sources. The company is seeking approval for its gene therapy for treating a rare muscle-wasting disorder called Duchenne muscular dystrophy under the FDA's accelerated pathway. Brokerage William Blair said it still sees a "likely" approval for the therapy. Shares of Catalent Inc (CTLT.N), which holds the contract manufacturing rights for the therapy, fell as much as 5.5% in early trade.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Deutsche Bank sees more than a 30% rally for this specialty biotech stock
▼ + stars: | 2023-04-10 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Deutsche Bank is more bullish on Catalent after the New Jersey-based company expanded its manufacturing partnership with Moderna . Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. CTLT YTD mountain Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share. Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. Stock Chart Icon Stock chart icon Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share.

☆ Citi says the recent selloff in this biotech stock is 'overdone,' predicts shares can rally 30% from here
▼ + stars: | 2023-04-04 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

The recent selloff in shares of Sarepta Therapeutics looks "overdone," according to Citi. Shares of Sarepta Therapeutics pulled back about 20% one day last month after regulators said they would hold an advisory committee meeting for SRP-9001, walking back previous plans to assess it without one. Despite these fears, Bitritto-Garg thinks an advisory committee was always in the cards for the treatment, but difficult to obtain as the FDA's Office of Therapeutic Products grappled with a restructuring and lack of resources. SRPT YTD mountain Shares so far this year She added that an advisory committee "may not be indicative of a meaningful change in FDA's position on the filing." Along with the buy rating, Bitritto-Garg slapped a $179 price target on shares, implying 30% upside from Monday's close.

Search resuls for: "Sarepta"

25 mentions found